참고문헌
- Aquerreta I, Aldaz A, Giraldez J, Sierrasesumaga L (2004). Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer, 42, 52-8. https://doi.org/10.1002/pbc.10443
- Chiba T, Yokosuka O, Fukai K, et al (2004). Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology, 66, 481-91. https://doi.org/10.1159/000079503
- Donadelli M, Costanzo C, Faggioli L, et al (2003). Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog, 38, 59-69. https://doi.org/10.1002/mc.10145
- Finnin MS, Donigian JR, Cohen A, et al (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-93. https://doi.org/10.1038/43710
-
Ghizzoni M, Haisma HJ, Maarsingh H, Dekker FJ (2011). Histone acetyltransferases are crucial regulators in NF-
${\kappa}B$ mediated inflammation. Drug Discov Today, 16, 504-11. https://doi.org/10.1016/j.drudis.2011.03.009 - Hirose T, Sowa Y, Takahashi S, et al (2003). p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene, 22, 7762-73. https://doi.org/10.1038/sj.onc.1207091
- Kim MS, Kwon HJ, Lee YM, et al (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 7, 437-43. https://doi.org/10.1038/86507
- Kim Y, Park H, Lim Y, et al (2003). Decreased syndecan-2 expression correlates with trichostatin-A inducedmorphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene, 22, 826-30. https://doi.org/10.1038/sj.onc.1206068
- Li MH, Miao ZH, Tan WF, et al (2004). Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res, 10, 8266-74. https://doi.org/10.1158/1078-0432.CCR-04-0951
- Liu LT, Chang HC, Chiang LC, Hung WC (2003). Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res, 63, 3069-72.
- Loidl P, Grobner P (1987). Postsynthetic acetylation of histones during the cell cycle: a general function for the displacement of histones during chromatin rearrangements. Nucleic Acids Res, 15, 8351-66. https://doi.org/10.1093/nar/15.20.8351
- Marks PA, Richon VM, Breslow R, Rifkind RA (2001). Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol, 13, 477-83. https://doi.org/10.1097/00001622-200111000-00010
- Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63. https://doi.org/10.1016/0022-1759(83)90303-4
- Muller M, Strand S, Hug H, et al (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest, 99, 403-13. https://doi.org/10.1172/JCI119174
- Sowa Y, Orita T, Minamikawa S, et al (1997). Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun, 241, 142-50. https://doi.org/10.1006/bbrc.1997.7786
- Strait KA, Dabbas B, Hammond EH,et al (2002). Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther, 1, 1181-90.
- Vigushin DM, Ali S, Pace PE, et al (2001). Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res, 7, 971-6.
- Williams RJ (2001). Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs, 10, 1571-3. https://doi.org/10.1517/13543784.10.8.1571
- Wolffe AP, Guschin D (2000). Review: chromatin structural features and targets that regulate transcription. J Struct Biol, 129, 102-22. https://doi.org/10.1006/jsbi.2000.4217
- Yoshida M, Horinouchi S, Beppu T (1995). Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays, 17, 423-30. https://doi.org/10.1002/bies.950170510
피인용 문헌
- Histone Deacetylase Inhibitor Trichostatin A Enhances Antitumor Effects of Docetaxel or Erlotinib in A549 Cell Line vol.13, pp.7, 2012, https://doi.org/10.7314/APJCP.2012.13.7.3471
- Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells vol.2013, pp.1369-1643, 2013, https://doi.org/10.1155/2013/608964
- Trichostatin A-induced Apoptosis is Mediated by Krüppel-like Factor 4 in Ovarian and Lung Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6581
- A New Cell Counting Method to Evaluate Anti-tumor Compound Activity vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3397
- TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells vol.30, pp.2, 2015, https://doi.org/10.1089/cbr.2014.1697
- Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line vol.6, pp.2, 2015, https://doi.org/10.1111/1759-7714.12167
- Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2693-3
- Metformin Synergistically Enhances Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A Against Osteosarcoma Cell Line vol.32, pp.4, 2013, https://doi.org/10.1089/dna.2012.1926
- HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells pp.1573-6822, 2019, https://doi.org/10.1007/s10565-019-09459-7